• Product NameSB1317(TG-02) hydrochloride
• Brief DescriptionInhibitors
• Purification98.00%
• Biological ActivitySB1317 is a potent inhibitor of CDK2, JAK2, and FLT3 for the treatment of cancer, with IC50 of 13, 73, and 56 nM for CDK2, JAK2 and FLT3, respectively.
• Target NameCDK inhibitor; FLT inhibitor; JAK inhibitor
• CAS No. T4227
• Calculated MW 408.92
• Formulation C23H25ClN4O
• Storage 3 years -20˚C powder;2 years -80˚C in solvent;

• Research Area:cancer
  SMILES:CN1C/C=C/CCOC2=CC=CC(=C2)C3=NC(=NC=C3)NC4=CC=CC(=C4)C1
  Pathways:Angiogenesis; Cell Cycle/Checkpoint; Chromatin/Epigenetic; Tyrosine Kinase/Adaptors; JAK/STAT signaling; Stem Cells
  Receptor:CDK2; FLT3; JAK2
  Boling pt:
  Melting pt:
  Solubility:DMSO: 26.5 mg/mL
  Appearance:
  Remark:For obtaining a higher solubility , please warm the tube at 37 ˚C and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20 ˚C for several month.

1. William AD, et al. Discovery of kinase spectrum selective macrocycle (16E)-14-methyl-20-oxa-5,7,14,26-tetraazatetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene (SB1317/TG02), a potent inhibitor of cyclin dependent kina

• Flow Cytometry (FCM) General Protocol
• Immunofluorescence(IC)
• Immunohistochemistry(Polymer)
• Western Blotting